Lexiva (fosamprenavir calcium) is indicated in combination with other antiretroviral agents for the treatment of HIV infection in adults. It was approved by the FDA for use in the US in 2003.
Recent research has shown that Lexiva boosted with ritonavir (Lexiva/r) offers comparable (non-inferior) efficacy and safety to lopinavir/r when both are given twice-daily as part of an HIV regimen in patients starting therapy. The International AIDS Society – USA (IAS-USA) has included Lexiva/r as a recommended component of initial antiretroviral therapy based on these data.
The IAS-USA commissions expert panels to issue recommendations and guidelines to provide standard approaches to patient care. The updated guidelines reflect the international perspectives of appointed panelists and are designed to serve as a tool for clinicians in countries where resources are sufficient to provide relatively unrestricted choices of drugs.